Samsung Biologics Earns Top Rating in ESG Risk Assessment

Sustainalytics Assessment Result
Earned a "Negligible" Rating

Samsung Biologics received the highest rating in a global environmental, social and governance (ESG) risk assessment.

A view of Samsung Biologics Plant 4 in Songdo, Yeonsu-gu, Incheon. Samsung Biologics.

On November 4, Samsung Biologics announced that it scored 9 points in Sustainalytics' "2026 ESG Risk Rating," earning the top rating of "Negligible." This marks a one-tier improvement from the "Low Risk" rating it received last year. The company ranked fourth among 842 pharmaceutical companies worldwide.

Sustainalytics is a subsidiary of Morningstar, a global investment research firm. Each year, it assesses the non-financial risks and management practices of approximately 16,000 companies worldwide. Ratings are divided into five tiers, with lower risk scores receiving better ratings. The top rating is given only to companies with scores below 10. Global institutional investors use the results as a key indicator when making investment decisions.

Samsung Biologics was recognized for enhancing its management systems across all ESG areas and expanding its disclosures. In the environmental area, it conducted environmental audits and developed plans to recycle hazardous waste. In the social area, it established a diversity policy and disclosed quality and safety goals. In the governance area, its ethics audits and the establishment of board diversity goals were reflected in the assessment.

John Rim, CEO of Samsung Biologics, said, "This result reflects our company-wide efforts to continuously enhance our ESG risk management system. We will continue to pursue responsible management and transparent disclosure to further strengthen the trust of global stakeholders."

This content was produced with the assistance of AI translation services.